Vitrolife och Biolamina increase collaboration within stem cells

Vitrolife AB (publ) has collaborated with the Stockholm-based Biolamina AB
within the stem-cell field since 2012. The companies have now decided to
increase their collaboration and, as part of this greater collaboration,
Vitrolife has invested in Biolamina together with the company’s present owners.
Vitrolife AB (publ) has collaborated with the Stockholm-based Biolamina AB
within the stem-cell field since 2012. During spring the collaboration resulted
in the launch of a new freeze medium for stem cells, FREEZEstem™, which has been
developed and produced by Vitrolife and is now marketed globally by Biolamina.

The companies have now decided to increase their collaboration and as part of
this increased collaboration Vitrolife has invested SEK 4 million in Biolamina
in a directed new share issue, which gives Vitrolife a 4.6% participation in the
company. Vitrolife takes possession of the shares in Biolamina as soon as the
share issue has been registered at the Swedish Companies Registration Office.
The investment is financed through Vitrolife’s cash reserves. Vitrolife will
also be represented on the company’s Board in the future.

“It is primarily researchers that today buy products to cultivate stem cells and
in a short period of time Biolamina has built up efficient marketing and
distribution channels aimed at these customers,” says Vitrolife’s CEO, Thomas
Axelsson. “The knowledge and infrastructure that underly Vitrolife’s success in
the fertility area are highly applicable to the stem-cell field as well, at the
same time as research into stem cells gives us knowledge to be able to improve
future fertility treatments.”

“We are pleased to be able to increase the collaboration between Vitrolife and
Biolamina and look forward to being able to access Vitrolife’s knowledge,
resources and network,” says Kristian Tryggvason, Biolamina’s CEO.

About Biolamina:

Biolamina commercializes innovations based on human recombinant proteins called
laminins, which solve the technical problems involved in the culture of
embryonic stem cells. By coating surfaces used for cell culture with recombinant
laminins, the natural environment in the body where these cells grow is
mimicked, and consequently the cells thrive and retain their function. These
innovations solve earlier problems of reliability and low cell quality, and
enable clinical development of new cell therapies. Biolamina reported revenue of
approximately SEK 7 million during the financial year 2012/2013. For more
information, see www.biolamina.com

November 13, 2013

Gothenburg

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
November 13, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 230
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/